Neurotoxic Antibodies against the Prion Protein Do Not Trigger Prion Replication.
Prions are the infectious agents causing transmissible spongiform encephalopathies (TSE), progressive, inexorably lethal neurological diseases. Antibodies targeting the globular domain (GD) of the cellular prion protein PrPC trigger a neurotoxic syndrome morphologically and molecularly similar to prion disease. This phenomenon raises the question whether such antibodies induce infectious prions de novo. Here we exposed cerebellar organotypic cultured slices (COCS) to the neurotoxic antibody, POM1. We then inoculated COCS homogenates into tga20 mice, which overexpress PrPC and are commonly utilized as sensitive indicators of prion infectivity. None of the mice inoculated with COCS-derived lysates developed any signs of disease, and all mice survived for at least 200 days post-inoculation. In contrast, all mice inoculated with bona fide prions succumbed to TSE after 55-95 days. Post-mortem analyses did not reveal any signs of prion pathology in mice inoculated with POM1-COCS lysates. Also, lysates from POM1-exposed COCS were unable to convert PrP by quaking. Hence, anti-GD antibodies do not catalyze the generation of prion infectivity. These data indicate that prion replication can be separated from prion toxicity, and suggest that anti-GD antibodies exert toxicity by acting downstream of prion replication.
Institute of Neuropathology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Karl
K
Frontzek
Institute of Neuropathology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Manuela
M
Pfammatter
Institute of Neuropathology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Silvia
S
Sorce
Institute of Neuropathology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Assunta
A
Senatore
Institute of Neuropathology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Petra
P
Schwarz
Institute of Neuropathology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Rita
R
Moos
Institute of Neuropathology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Katrin
K
Frauenknecht
Institute of Neuropathology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Simone
S
Hornemann
Institute of Neuropathology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Adriano
A
Aguzzi
PLoS One. 2015 Dec 14;10(12):e0144983
26658276
Nature. 1996 Jan 25;379(6563):339-43
8552188
EMBO J. 1996 Mar 15;15(6):1255-64
8635458
FEBS J. 2009 Apr;276(8):2359-67
19348007
Mol Biol Cell. 2007 Sep;18(9):3302-12
17567949
PLoS Pathog. 2015 Feb 24;11(2):e1004662
25710374
J Exp Med. 2016 May 30;213(6):1047-59
27185853
Nat Neurosci. 2008 Jan;11(1):109-17
18066056
FEBS Lett. 1997 Nov 17;417(3):400-4
9409760
Nature. 1997 Oct 23;389(6653):795-8
9349807
PLoS Pathog. 2016 Jan 28;12(1):e1005401
26821311
Prion. 2011 Jul-Sep;5(3):150-3
21778820
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9295-9
11470893
Nature. 1997 Sep 4;389(6646):69-73
9288968
Nat Neurosci. 2012 Jun 26;15(7):936-9
22735515
Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20908-13
18077360
Nature. 2013 Sep 5;501(7465):102-6
23903654
Nat Rev Mol Cell Biol. 2007 Jul;8(7):552-61
17585315
Brain. 2013 Apr;136(Pt 4):1102-15
23550113